ArticleJournal of pharmaceutical health care and sciences2025
Population pharmacokinetics and pharmacogenomics of edoxaban in Japanese adults with atrial fibrillation.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacogenomics of direct oral anticoagulants: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundEdoxaban is used as an anti-coagulant to prevent cardioembolic infarction, deep vein thrombosis, and pulmonary embolism. Edoxaban pharmacokinetics have been reported to be affected by several factors such as renal function, age, body weight, and the concomitant use of P-glycoprotein inhibitors. However, the relationship between genetic polymorphisms in drug metabolizing enzymes and transporters and the inter-individual variability of edoxaban pharmacokinetics in patients with atrial fibrillation (AF) remains unclear. Additionally, there is little information concerning PPK analysis using real world data. In this study a population pharmacokinetic and pharmacogenomic analysis was conducted to clarify covariate factors affecting the edoxaban pharmacokinetics in Japanese adult AF patients.
methodsOne hundred and thirty-one blood samples were collected from 131 patients. The edoxaban pharmacokinetic profile was described by a one-compartment model, and pharmacogenomic data were stratified according to CYP3A5 (CYP3A5*3) and ABCB1 (ABCB1 1236 C > T, 2677G > T/A, and 3435 C > T) polymorphisms. A non-linear mixed-effects modeling software (NONMEM™) was used to evaluate the effects of patient characteristics and genetic polymorphisms on the edoxaban pharmacokinetics.
resultsThe apparent oral clearance (CL/F) of edoxaban was estimated, and the apparent volume of distribution was fixed at the reported value. The CL/F of edoxaban was correlated non-linearly with creatinine clearance (CLcr), wherein the population mean CL/F for a typical patient (CLcr = 61.8 mL/min) was estimated to be 28.2 L/h. Other clinical laboratory data and genetic polymorphisms, excluding CLcr, did not affect the edoxaban pharmacokinetics.
conclusionsThese results suggest that genetic polymorphisms of CYP3A5 and ABCB1 are not considered intrinsic factors affecting edoxaban pharmacokinetics in Japanese adult AF patients. Similarly to previous studies, renal function affects its pharmacokinetics. These findings may provide useful information for individualized anticoagulant therapy with edoxaban to prevent adverse events without reference to genetic polymorphisms of CYP3A5 and ABCB1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.